RxDoctor Payments Data

David Brandt, MD

Internal Medicine · Chicago, ILNPI 1629004965

Payments from drug & device makers

$2,660in general payments, 2019–2025

Across 132 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$911
  • Gilead$906
  • Johnson & Johnson$314
  • Merck$217
  • Dynavax Technologies Corporation$74
  • Napo Pharmaceuticals Inc$40
  • plus $198 from 9 others

What the payments were for

  • Speaking & faculty fees$221%
  • Food & beverage$2,63899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,660 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$1,559
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$82,718
OzempicSemaglutide34$79,590
EliquisApixaban84$68,829
EntrestoSacubitril/Valsartan24$39,336
XareltoRivaroxaban39$37,432
RybelsusSemaglutide20$32,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$25,380
FarxigaDapagliflozin Propanediol29$24,298
JanuviaSitagliptin Phosphate14$21,502
TrulicityDulaglutide11$14,053
SymbicortBudesonide/Formoterol Fumarate47$13,987
Incruse ElliptaUmeclidinium Bromide28$11,367
Spiriva HandihalerTiotropium Bromide19$9,644
Breo ElliptaFluticasone/Vilanterol12$7,086
Combivent RespimatIpratropium/Albuterol Sulfate13$6,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$112,35454 claims
PfizerEliquis$16$68,82984 claims
Johnson & JohnsonXarelto$314$37,43239 claims
MerckJanuvia$217$21,50214 claims
Lilly USA, LLCTrulicity$36$14,05311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →